drugset / Trial / NCT05380479
Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients.
RandomizedParallel-groupDouble-blindTreatment
Summary
This study was 8 weeks randomized, double-blind trail to assess the effect of mirtazapine versus megestrol acetate in treatment of anorexia-cachexia in advanced cancer patients in 80 patients. Participants were assessed at baseline, 4 weeks and 8 weeks. Subject were randomized to receive either mirtazapine 15 mg tablet daily or megestrol acetate 160 mg tablet daily for 8 weeks. The primary outcome was the measure of FAACT(A/C) score and the secondary measure includes weight, BMI, quality of life and evaluate adverse effects.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2023-01-01
- Completion
- 2023-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Megestrol Acetate | Other / unclassified | 160 mg | Oral |
| Subject | Mirtazapine | Other / unclassified | 15 mg | Oral |